Oral antidiabetic drugs (OADs) are widely used to treat type 2 diabetes mellitus (T2DM). However, inherited difference is one of the major issues that affect OADs therapeutic efficacy. In the present paper, we performed a critical review on recent advances in genetic polymorphisms that influence OADs therapeutic efficacy and metabolism. Sulfonylureas (SUs), Meglitinides, Metformin and Thiazolidinediones (TZDs) will be discussed.
Citation: Yin J, Guo Y, Huang Q, Sun H, Zhou H, et al. (2012) Pharmacogenetics of Oral Antidiabetic Drugs: Potential Clinical Application. Endocrinol Metabol Syndrome S5:003. doi: 10.4172/2161-1017.S5-003